Parents & Patients
Finally! A simple, engaging, and effective alternative to patching is here!
How luminopia works
Luminopia is the first FDA-approved* binocular therapy for amblyopia. With Luminopia, patients can choose from more than 700 hours of popular TV shows and movies to watch within a virtual reality (VR) headset. Whether it’s Wild Kratts, Spongebob, or Sesame Street, our software algorithms take the content, modify it in real-time, and present it differently to each eye to rebalance the input to the brain.
Unlike eye-patches which just block the strong eye image, Luminopia teaches patients to use both eyes together. Thanks to the power of VR headsets, treatment is delivered in a controlled environment with no distractions. Images within the headset are also projected at optical infinity, so there’s no need to worry about your child being too close to a screen.
Luminopia works on off-the-shelf VR headsets, and if you don't own one, we'll send you one to use for the duration of treatment. The recommended dose for Luminopia is 1 hour a day, 6 days a week, until your eye-care professional determines that treatment is complete.
Patient Education Video
700+ Hours of Popular Kids Shows and Movies
These are just some of the shows that children will be able to watch while using Luminopia.
Ready Jet Go!
Max & Ruby
How To Train Your Dragon
Unlike eye patches or blurring drops, Luminopia improves vision in amblyopia by treating the eyes in two different ways
The contrast of the stronger eye image is reduced to encourage the brain to pay more attention to the weaker eye
Complementary Masks remove parts of each eye’s image, teaching the brain to combine input from both eyes
Clinically Proven and Parent Approved
compliance with full dose of 1 hr/day, 6 days/week over 12 weeks
of kids experience vision improvement after treatment
prefer Luminopia over patching
how to get started on luminopia
Your doctor will send a prescription to PhilRx, our pharmacy partner.
PhilRx will text you to complete enrollment and walk you through the process to check for coverage.
PhilRx will collect payment, ship you a loaner VR headset, and text you an access code to begin treatment.
When treatment is complete, return the headset using a prepaid shipping label from PhilRx.
1 - Xiao, S., Angjeli, E., Wu, H. C., Gaier, E. D., Gomez, S., Travers, D. A., Binenbaum, G., Langer, R., Hunter, D. G., & Repka, M. X. (2022). Randomized controlled trial of a dichoptic digital therapeutic for Amblyopia. Ophthalmology, 129(1), 77–85.
*De Novo granted in Oct 2021.
Indications, Safety and Warnings
Luminopia is a software-only digital therapeutic designed to be used with commercially available Head-Mounted Displays (HMDs) which are compatible with the software application. Luminopia is indicated for improvement in visual acuity in amblyopia patients, aged 4-7, associated with anisometropia and/or with mild strabismus, having received treatment instructions (frequency and duration) as prescribed by a trained eye-care professional. Luminopia is intended for both previously treated and untreated patients; however, patients with more than 12 months of prior treatment (other than refractive correction) have not been studied. Luminopia is intended to be used as an adjunct to full-time refractive correction, such as glasses, which should also be worn under the HMD during Luminopia therapy. Luminopia is intended for Prescription Use Only, in an at-home environment.
In the Luminopia pivotal trial, 14 patients (25%) experienced adverse events in the treatment group vs. 8 (14%) in the control group. Ocular AEs were reported in 6 (11%) patients in the treatment group and 8 (14%) patients in the control. No serious adverse events (AEs) were reported. The most frequent non-serious AE potentially related to Luminopia was headache (14.3%), for which all cases were graded as mild, transient, and resolved without sequelae.
Rx only: Federal law restricts this device on the order of a trained eye-care professional.
Safety and effectiveness of Luminopia beyond 12 weeks is unknown. The long-term effects of HMD use in patients 4-7 years of age are unknown. Patients with a history of light-induced seizures, or serious medical conditions, should contact a doctor before using Luminopia. Patients should only use Luminopia while wearing their prescribed glasses under the HMD. Patients should stop using Luminopia and contact a doctor if they experience a new or worsened eye-turn, or double vision. Patients with an interpupillary distance of less than 52 mm should not use Luminopia.
Sign up to stay updated on our launch
Copyright 2023 © Luminopia, Inc. All rights reserved.